ARA-290 vs PEA
A side-by-side research comparison of ARA-290 and PEA across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ARA-290 | PEA |
|---|---|---|
| Full name | Cibinetide (ARA-290) | Palmitoylethanolamide |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Investigational | Dietary supplement (medical food in EU) |
| Mechanism | Selectively activates the innate repair receptor (a heteromer of the EPO receptor and the beta-common receptor), triggering anti-inflammatory and tissue-protective signaling while avoiding hematopoietic stimulation. | Activates PPARĪ± nuclear receptors for anti-inflammatory gene transcription. Inhibits mast cell degranulation. Enhances endocannabinoid tone by inhibiting FAAH (increasing anandamide). Desensitizes TRPV1 pain channels via allosteric modulation. |
| Molecular weight | ~1257 Da | 299.49 Da |
| Half-life | Short (minutes in plasma); effects outlast plasma levels | ~1-2 hours (micronized form extends effects) |
| Bioavailability | High via subcutaneous injection | ~20% (standard); improved with micronized/ultra-micronized forms |
| Typical dose | 1-4 mg per dose | 300-1200 mg |
| Frequency | Daily during a course | 2-3x daily |
| Route | Subcutaneous injection | Oral (micronized preferred) |
ARA-290 reported benefits
- Reduces neuropathic pain
- Anti-inflammatory tissue protection
- Supports small-fiber nerve repair
- No increase in red blood cell mass (unlike EPO)
PEA reported benefits
- Chronic pain reduction
- Neuropathic pain relief
- Anti-inflammatory (mast cell stabilization)
- No tolerance or dependence
- Neuroprotection
- Safe with other medications
Related comparisons
Research and educational reference only. Not medical advice.